MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome
| Autor: | M Cizmarikova, Jan Mojzis, V Habalova, Mirossay A, Kohút A, L Schonova, M Wagnerova, Ladislav Mirossay, A Linkova, Marek Sarissky |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Oncology medicine.medical_specialty ATP Binding Cassette Transporter Subfamily B Anthracycline medicine.medical_treatment Breast Neoplasms Biology Polymorphism Single Nucleotide Breast cancer Gene Frequency Risk Factors Internal medicine Genetics medicine Humans Anthracyclines ATP Binding Cassette Transporter Subfamily B Member 1 Pathological Allele frequency Neoadjuvant therapy Aged Retrospective Studies Aged 80 and over Pharmacology Chemotherapy Middle Aged medicine.disease Hematologic Diseases Neoadjuvant Therapy Exact test Treatment Outcome Immunology Disease Progression Molecular Medicine Female Breast carcinoma |
| Zdroj: | The Pharmacogenomics Journal. 10:62-69 |
| ISSN: | 1473-1150 1470-269X |
| Popis: | P-glycoprotein (PGP), the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of carcinogens and cytostatics. It has been suggested that MDR1 polymorphisms contribute to the variability in cancer risk and therapeutic outcome. We examined the relevance of C3435T polymorphism in relation to breast cancer susceptibility, clinical and pathological characteristics of breast carcinoma, the therapeutic response and hematologic toxicities after anthracycline-based chemotherapy. A significant association between allele frequencies and histological type, stage and histological grade was observed (P=0.024, 0.014, 0.006, respectively, chi(2)-test or Fisher's exact test). We also found significantly higher (P=0.019, chi(2)-test) T allele frequency in breast cancer patients (n=221) than in controls (n=113). A significantly enhanced therapeutic outcome after neoadjuvant therapy (n=38; P=0.021, Fisher's exact test) and longer time to progression after anthracycline-based chemotherapy (n=102; P=0.049, log-rank test) were observed in CC homozygotes. However, no significant association between hematologic toxicities and C3435T polymorphism was detectable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|